STRATA CRITICAL MEDICAL INC (SRTA) Fundamental Analysis & Valuation

NASDAQ:SRTA • US0926671043

Current stock price

5.03 USD
+0.13 (+2.65%)
Last:

This SRTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SRTA Profitability Analysis

1.1 Basic Checks

  • SRTA had negative earnings in the past year.
  • In the past year SRTA has reported a negative cash flow from operations.
  • SRTA had negative earnings in 4 of the past 5 years.
  • In the past 5 years SRTA always reported negative operating cash flow.
SRTA Yearly Net Income VS EBIT VS OCF VS FCFSRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

1.2 Ratios

Industry RankSector Rank
ROA 12.7%
ROE 14.82%
ROIC N/A
ROA(3y)-5.65%
ROA(5y)-7.41%
ROE(3y)-7.14%
ROE(5y)-9.03%
ROIC(3y)N/A
ROIC(5y)N/A
SRTA Yearly ROA, ROE, ROICSRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • The Operating Margin and Gross Margin are not available for SRTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 17.14%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRTA Yearly Profit, Operating, Gross MarginsSRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SRTA Health Analysis

2.1 Basic Checks

  • SRTA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SRTA has been increased compared to 5 years ago.
  • There is no outstanding debt for SRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRTA Yearly Shares OutstandingSRTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
SRTA Yearly Total Debt VS Total AssetsSRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.43 indicates that SRTA is not in any danger for bankruptcy at the moment.
  • There is no outstanding debt for SRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.43
ROIC/WACCN/A
WACCN/A
SRTA Yearly LT Debt VS Equity VS FCFSRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • SRTA has a Current Ratio of 6.38. This indicates that SRTA is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 6.38 indicates that SRTA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.38
SRTA Yearly Current Assets VS Current LiabilitesSRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SRTA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.73% over the past year.
  • SRTA shows a decrease in Revenue. In the last year, the revenue decreased by -3.02%.
  • The Revenue has been growing by 10.50% on average over the past years. This is quite good.
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y10.5%
Revenue growth 5YN/A
Sales Q2Q%22.87%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.03% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 13.35% on average over the next years. This is quite good.
EPS Next Y45.08%
EPS Next 2Y40.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.89%
Revenue Next 2Y17.19%
Revenue Next 3Y14.15%
Revenue Next 5Y13.35%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SRTA Yearly Revenue VS EstimatesSRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M
SRTA Yearly EPS VS EstimatesSRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. SRTA Valuation Analysis

4.1 Price/Earnings Ratio

  • SRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SRTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTA Price Earnings VS Forward Price EarningsSRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRTA Per share dataSRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • SRTA's earnings are expected to grow with 40.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.03%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRTA Dividend Analysis

5.1 Amount

  • No dividends for SRTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRTA Fundamentals: All Metrics, Ratios and Statistics

STRATA CRITICAL MEDICAL INC

NASDAQ:SRTA (4/30/2026, 1:11:24 PM)

5.03

+0.13 (+2.65%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-03
Earnings (Next)05-11
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change5.87%
Market Cap0
Revenue(TTM)241.19M
Net Income(TTM)41.35M
Analysts84
Price Target8.99 (78.73%)
Short Float %N/A
Short Ratio7.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-233.33%
Min EPS beat(2)-370.59%
Max EPS beat(2)-96.08%
EPS beat(4)1
Avg EPS beat(4)-103.27%
Min EPS beat(4)-370.59%
Max EPS beat(4)64.99%
EPS beat(8)3
Avg EPS beat(8)-61.76%
EPS beat(12)5
Avg EPS beat(12)-51.87%
EPS beat(16)8
Avg EPS beat(16)-29.75%
Revenue beat(2)2
Avg Revenue beat(2)9.17%
Min Revenue beat(2)8.5%
Max Revenue beat(2)9.84%
Revenue beat(4)4
Avg Revenue beat(4)8.59%
Min Revenue beat(4)7.7%
Max Revenue beat(4)9.84%
Revenue beat(8)7
Avg Revenue beat(8)5.61%
Revenue beat(12)10
Avg Revenue beat(12)5.52%
Revenue beat(16)14
Avg Revenue beat(16)8.37%
PT rev (1m)-8.44%
PT rev (3m)-8.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30%
EPS NY rev (1m)-154.54%
EPS NY rev (3m)-154.54%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)1.56%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.71
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 2.88
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS2.94
BVpS3.4
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 12.7%
ROE 14.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 17.14%
GM N/A
FCFM N/A
ROA(3y)-5.65%
ROA(5y)-7.41%
ROE(3y)-7.14%
ROE(5y)-9.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.51%
Cap/Sales 4.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.38
Altman-Z 3.43
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)239.19%
Cap/Depr(5y)156.06%
Cap/Sales(3y)6.6%
Cap/Sales(5y)4.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y45.08%
EPS Next 2Y40.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y10.5%
Revenue growth 5YN/A
Sales Q2Q%22.87%
Revenue Next Year25.89%
Revenue Next 2Y17.19%
Revenue Next 3Y14.15%
Revenue Next 5Y13.35%
EBIT growth 1Y-562.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year363.46%
EBIT Next 3Y76.53%
EBIT Next 5Y56.68%
FCF growth 1Y-68.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1841.8%
OCF growth 3YN/A
OCF growth 5YN/A

STRATA CRITICAL MEDICAL INC / SRTA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRTA.


What is the valuation status of STRATA CRITICAL MEDICAL INC (SRTA) stock?

ChartMill assigns a valuation rating of 1 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.


How profitable is STRATA CRITICAL MEDICAL INC (SRTA) stock?

STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SRTA stock?

The Earnings per Share (EPS) of STRATA CRITICAL MEDICAL INC (SRTA) is expected to grow by 45.08% in the next year.